Boronated monoclonal antibody 17-1A for potential neutron capture therapy of colorectal cancer.
The theoretical basis for boron neutron capture therapy (BNCT) derives from the reaction that occurs when a stable isotope, boron-10, is irradiated with thermal neutrons to produce an unstable intermediate, boron-11, which then undergoes instantaneous nuclear fission to yield lithium-7 and alpha particles.